Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).
Company profile
Ticker
ALT
Exchange
Website
CEO
Vipin Garg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEALTHCARE ACQUISITION CORP, PHARMATHENE, INC
SEC CIK
Corporate docs
Subsidiaries
Altimmune, LLC • Altimmune UK, Limited • Spitfire Pharma, LLC • Altimmune AU Pty, Limited ...
IRS number
202726770
ALT stock data
Analyst ratings and price targets
Current price
Average target
$23.67
Low target
$20.00
High target
$26.00
Evercore ISI Group
Maintains
$25.00
Goldman Sachs
Initiated
$20.00
JMP Securities
Maintains
$26.00
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
20 Dec 22
CT ORDER
Confidential treatment order
29 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
10 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
29 Sep 22
8-K
Regulation FD Disclosure
14 Sep 22
DEF 14A
Definitive proxy
16 Aug 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Transcripts
ALT
Earnings call transcript
2022 Q3
10 Nov 22
ALT
Earnings call transcript
2022 Q2
11 Aug 22
ALT
Earnings call transcript
2022 Q1
12 May 22
ALT
Earnings call transcript
2021 Q4
15 Mar 22
ALT
Earnings call transcript
2021 Q3
10 Nov 21
ALT
Earnings call transcript
2021 Q2
11 Aug 21
ALT
Earnings call transcript
2021 Q1
17 May 21
ALT
Earnings call transcript
2020 Q4
25 Feb 21
ALT
Earnings call transcript
2020 Q3
10 Nov 20
ALT
Earnings call transcript
2020 Q2
12 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 127.50 mm | 127.50 mm | 127.50 mm | 127.50 mm | 127.50 mm | 127.50 mm |
| Cash burn (monthly) | 2.80 mm | 3.95 mm | 8.25 mm | 7.39 mm | 5.02 mm | 5.60 mm |
| Cash used (since last report) | 11.81 mm | 16.68 mm | 34.83 mm | 31.18 mm | 21.18 mm | 23.66 mm |
| Cash remaining | 115.69 mm | 110.82 mm | 92.67 mm | 96.32 mm | 106.32 mm | 103.84 mm |
| Runway (months of cash) | 41.4 | 28.1 | 11.2 | 13.0 | 21.2 | 18.5 |
Institutional ownership, Q3 2022
37.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 161 |
| Opened positions | 29 |
| Closed positions | 33 |
| Increased positions | 59 |
| Reduced positions | 56 |
| 13F shares | Current |
|---|---|
| Total value | 477.39 mm |
| Total shares | 18.24 mm |
| Total puts | 297.40 k |
| Total calls | 530.60 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Tiaa Cref Investment Management | 2.21 mm | $20.24 mm |
| Teachers Advisors | 2.21 mm | $20.24 mm |
| BLK Blackrock | 2.07 mm | $64.06 mm |
| BEN Franklin Resources | 1.31 mm | $40.38 mm |
| Franklin Mutual Advisers | 1.31 mm | $55.13 mm |
| Vanguard | 1.16 mm | $35.68 mm |
| Neuberger Berman | 636.80 k | $19.69 mm |
| Nuveen Asset Management | 572.16 k | $17.67 mm |
| Dimensional Fund Advisors | 482.82 k | $14.91 mm |
| IVZ Invesco | 461.34 k | $14.25 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Feb 23 | Vipin K Garg | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 13.78 | 7,658 | 105.53 k | 238,601 |
| 1 Feb 23 | Vipin K Garg | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 16,546 | 0.00 | 246,259 |
| 1 Feb 23 | Vipin K Garg | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 16,546 | 0.00 | 33,090 |
| 1 Feb 23 | M Scot Roberts | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 13.78 | 2,183 | 30.08 k | 14,456 |
| 1 Feb 23 | M Scot Roberts | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 6,166 | 0.00 | 16,639 |
| 1 Feb 23 | M Scot Roberts | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 6,166 | 0.00 | 12,332 |
| 1 Feb 23 | Matthew Scott Harris | Common Stock, par value $0.0001 | Payment of exercise | Dispose F | No | No | 13.78 | 2,183 | 30.08 k | 17,900 |
| 1 Feb 23 | Matthew Scott Harris | Common Stock, par value $0.0001 | Option exercise | Acquire M | No | No | 0 | 6,166 | 0.00 | 20,083 |
| 1 Feb 23 | Matthew Scott Harris | RSU Common Stock, par value $0.0001 | Option exercise | Dispose M | No | No | 0 | 6,166 | 0.00 | 12,332 |
| 31 Jan 23 | Richard I Eisenstadt | Common Stock, par value $0.0001 | Grant | Acquire A | No | No | 10.2085 | 1,172 | 11.96 k | 12,010 |
News
4 Analysts Have This to Say About Altimmune
20 Jan 23
HC Wainwright & Co. Reiterates Buy on Altimmune, Announces $50 Price Target
20 Jan 23
Evercore ISI Group Maintains Outperform on Altimmune, Raises Price Target to $25
18 Jan 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
16 Jan 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
13 Jan 23
Press releases
Altimmune Appoints Raymond Jordt as Chief Business Officer
4 Jan 23
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
4 Jan 23
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
20 Dec 22
Thinking about buying stock in Altimmune, Lordstown Motors, Sonim Technologies, Nutanix, or RA Medical?
1 Dec 22
Altimmune to Participate at Two Upcoming Investor Conferences
22 Nov 22